Skip to main content

A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Pfizer, Inc.

Start Date

September 1, 2016

End Date

July 15, 2020
 

Administered By

Duke Cancer Institute

Awarded By

Pfizer, Inc.

Start Date

September 1, 2016

End Date

July 15, 2020